Skip to Content

Symptom Assessment of Cancer Patients Undergoing Autologous Blood or Marrow Transplantations

Principal Investigator: Karen O. Anderson, Ph.D.

Patients who undergo autologous transplantations typically report multiple physical, cognitive and affective symptoms during the acute and post-transplant periods. Longitudinal studies are needed to provide a comprehensive assessment of the frequency, severity, and patterns of physical, cognitive and affective symptoms that patients experience. Also, very little is known about the symptoms of patients who do not survive, as compared to the symptoms of the patients who survive. In the proposed study, we will assess the symptoms of patients undergoing autologous transplantation who are at high risk of dying from their underlying disease.

Specific Goals

  • To assess the symptoms of breast cancer, non-Hodgkin’s lymphoma and multiple myeloma patients following autologous transplantation in order to identify changes in symptoms and symptom patterns during the first two years post-transplant
  • To determine the relationships among symptoms, functional status, quality of life and length of survival during the two year post-transplant period for breast cancer, non-Hodgkin’s lymphoma and multiple myeloma patients 
  • To evaluate the usefulness of an interactive voice response (IVR) telephone system for symptom assessment of breast cancer, non-Hodgkin’s lymphoma

Methods

Screening and enrollment for this study will occur in the outpatient autologous transplantation clinic. Patients who agree to participate in the study will complete questionnaires assessing symptoms, cognitive function, quality of life and family function. The patients’ symptoms will be assessed during their hospitalization for the pre-transplant conditioning regimen and transplantation. After discharge from the hospital, the patients’ symptoms will be assessed for two years post-transplantation using an interactive voice response (IVR) telephone system.

Measures

The measures include the Brief Pain Inventory (BPI), the Brief Fatigue Inventory (BFI), the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT), the MD Anderson Symptom Inventory (MDASI), the MOS 12-Item Short-Form Health Survey (SF-12) and the Profile of Mood States (POMS) and a set of neurocognitive tests.

For more information

Contact: Jane Brown, B.S.N., C.R.R.N., at janbrown@mdanderson.org


© 2014 The University of Texas MD Anderson Cancer Center